Interventions for hereditary haemochromatosis: An attempted network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2017, Pages

  Buzzetti, Elena ^a   Kalafateli, Maria ^a   Thorburn, Douglas ^a   Davidson, Brian R ^b   Tsochatzis, Emmanuel ^a   Gurusamy, Kurinchi Selvan ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN;

ERYTHROCYTE; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HUMAN; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; META ANALYSIS; NETWORK META-ANALYSIS; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; CYTAPHERESIS; GENETICS; MIDDLE AGED; MORTALITY; PROCEDURES; QUALITY OF LIFE; TIME FACTOR;

ADULT; CYTAPHERESIS; ERYTHROCYTES; HEMOCHROMATOSIS; HUMANS; MIDDLE AGED; PHLEBOTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 85014753020     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011647.pub2     Document Type: Review

References (77)

1. Rombout-Sestrienkova E, Nieman FH, Essers BA, Noord PA, Janssen MC, Deursen CT, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012;52(3):470-7. 5303243
2. Rombout-Sestrienkova E, Noord P, Reuser E, Heeremans J, Deursen C, Janssen M, et al. Therapeutic erythrocytapheresis (TE) versus phlebotomy (P) in the treatment of hereditary hemochromatosis (HH) patients: preliminary results from an ongoing randomized clinical trial (NCT 00202436). Transfusion and Apheresis Science 2009;40(2):135-6. 5303244
3. Rombout-Sestrienkova E, Winkens B, Essers BA, Nieman FH, Noord PA, Janssen MC, et al. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial. Transfusion 2016;56(1):261-70. 5303246
4. Sundic T, Hervig T, Hannisdal S, Assmus J, Ulvik RJ, Olaussen RW, et al. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis. Blood Transfusion 2014;12(Suppl 1):S84-9. 5303248
5. Ong SY, Dolling L, Dixon JL, Nicoll AJ, Gurrin LC, Wolthuizen M, et al. Should HFE p.C282y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). BMJ Open 2015;5(8):e008938. 5303250
6. Adams PC, Barton JC. Haemochromatosis. Lancet 2007;370(9602):1855-60.
7. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. New England Journal of Medicine 2008;358(3):221-30.
8. Assi TB, Baz E. Current applications of therapeutic phlebotomy. Blood Transfusion 2014;12(Suppl 1):s75-83.
9. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS, American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 2011;54(1):328-43.
10. Bardou-Jacquet E, Brissot P. Diagnostic evaluation of hereditary hemochromatosis (HFE and non-HFE). Hematology/Oncology Clinics of North America 2014;28(4):625-35.
11. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G → A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359(9302):211-8.
12. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. Journal of Medical Screening 1996;3(4):178-84.
13. Cancado R, Melo MR, de Moraes Bastos R, Santos PC, Guerra-Shinohara EM, Ballas SK, et al. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-year Phase 2 study. European Journal of Haematology 2015;95(6):545-50.
14. Cassanelli S, Pignatti E, Montosi G, Garuti C, Mariano M, Campioli D, et al. Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. Journal of Hepatology 2001;34(4):523-8.
15. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Research Synthesis Methods 2012;3(2):161-76.
16. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS one 2013;8(10):e76654.
17. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7.
18. de Graaff B, Neil A, Sanderson K, Si L, Yee KC, Palmer AJ. A systematic review and narrative synthesis of health economic studies conducted for hereditary haemochromatosis. Applied Health Economics and Health Policy 2015;13(5):469-83.
19. Del Re AC, Spielmans GI, Flückiger C, Wampold BE. Efficacy of new generation antidepressants: differences seem illusory. PLoS One 2013;8(6):e63509.
20. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
22. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29(7-8):932-44.
23. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment, September 2011 (last updated April 2012). www.nicedsu.org.uk/TSD3%20Heterogeneity.final%20report.08.05.12.pdf (accessed 27 March 2014).
24. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: introduction to evidence synthesis for decision making, April 2011 (last updated April 2012). www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf (accessed 27 March 2014).
25. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, August 2011 (last updated April 2014). www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf (accessed 8 October 2014).
26. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials, May 2011 (last updated April 2014). www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf (accessed 8 October 2014).
27. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. Journal of Hepatology 2010;53(1):3-22.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
29. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66, 000 cases and 226, 000 controls. Hepatology 2007;46(4):1071-80.
30. EuroQol . About EQ-5D, 2014. www.euroqol.org/about-eq-5d.html (accessed 8 October 2014).
31. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics 1996;13(4):399-408.
32. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)). 2015, Issue 11. Art. No.: LIVER.
33. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
34. Higgins JPT, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
35. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Research Synthesis Methods 2012;3(2):98-110.
36. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997.
37. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14(1):120.
38. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
39. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101(474):447-59.
40. Lucotte G, Dieterlen F. A European allele map of the C282Y mutation of hemochromatosis: Celtic versus Viking origin of the mutation?. Blood, Cells, Molecules & Diseases 2003;31(2):262-7.
41. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]
42. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-54.
43. Sweetman S, editor . Martindale: the complete drug reference (online version), 37th edition, 2011. www.pharmpress.com/product/MC_MART/martindale-the-complete-drug-reference (accessed 23 September 2014).
44. Mercier G, Bathelier C, Lucotte G. Frequency of the C282Y mutation of hemochromatosis in five French populations. Blood, Cells, Molecules & Diseases 1998;24(2):165-6.
45. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308(12):1246-53.
46. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
47. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-41.
48. Members of OpenBUGS Project Management Group. OpenBUGS. Version 3.2.3. Members of OpenBUGS Project Management Group, 2014.
49. Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood 2014;123(10):1447-54.
50. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. New England Journal of Medicine 2004;350(23):2383-97.
51. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ (Clinical Research Ed.) 2014;349:g5630.
52. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
53. Ropero P, Briceno O, Mateo M, Polo M, Mora A, Gonzalez FA, et al. Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in a cohort of 1, 000 neonates in Madrid (Spain). Annals of Hematology 2006;85(5):323-6.
54. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
55. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71.
56. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):80-97.
57. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82.
58. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
59. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Annals of Internal Medicine 2005;143(7):522-36.
60. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
61. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical Research Ed.) 2010;340:c332.
62. Severini TA. Bayesian interval estimates which are also confidence intervals. Journal of the Royal Statistical Society. Series B (Methodological) 1993;55(2):533-40.
63. StataCorp LP. Stata/SE 14.2 for Windows[64-bit x86-64]. Version 14. College Station: StataCorp LP, 2017.
64. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285(17):2216-22.
65. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. 2011. p. 1-115. Available from www.ctu.dk/tsa.
66. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Systematic Reviews 2012;1:41.
67. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen. TSA version 0.9. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, 2011.
68. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818-27.
69. van Bokhoven MA, van Deursen CT, Swinkels DW. Diagnosis and management of hereditary haemochromatosis. BMJ (Clinical Research Ed.) 2011;342:c7251.
70. van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Research Synthesis Methods 2012;3(4):285-99.
71. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology 2007;136(3):501-8.
72. Voicu PM, Cojocariu C, Petrescu-Danila E, Covic M, Stanciu C, Rusu M. Prevalence of HFE (hemochromatosis) gene mutations C282Y and H63D in a Romanian population. Blood, Cells, Molecules & Diseases 2009;42(1):14-5.
73. Ware JE. SF-36® health survey update, 2014. www.sf-36.org/tools/sf36.shtml (accessed on 8 October 2014).
74. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
75. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2006;145(3):209-23.
76. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC. Natural history of C282Y homozygotes for hemochromatosis. Canadian Journal of Gastroenterology 2002;16(5):297-302.
77. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.